A Phase 2 interventional study of Olaparib and Ceralasertib in Ovarian Cancer, sponsored by AstraZeneca. Withdrawn at 26 sites in 4 countries. Open to female participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2021-03-10.
Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 69 studies testing olaparib in Ovarian Neoplasms — 13 open to participants now, 26 under way, 9 of them phase 3. olaparib · Ovarian Neoplasms.
Among the 69 studies testing olaparib in Ovarian Neoplasms, this one is the 65th largest by enrollment, is one of 6 that started in 2020, is one of 32 in phase 2, and was the 42nd registered.
3,387 studies on the registry are indexed under Ovarian Neoplasms; 792 are open to participants now.
Browse Ovarian Neoplasms studies →13 of the 69 studies testing olaparib in Ovarian Neoplasms are open now, in 8 countries. Recruiting first, the newest first:
Bai-Rong Xia · Sites in China
Ages 18–75 · Women only
Daewoong Pharmaceutical Co. LTD. · Sites in Korea, Republic of
Ages 19+ · Women only
Boryung Pharmaceutical Co., Ltd · Sites in Korea, Republic of
Ages 19–74 · Women only
The Netherlands Cancer Institute · Sites in Netherlands
Ages 18–100 · Women only
NRG Oncology · Sites in United States, Japan, Puerto Rico
Ages 18+
By country, each count listing its studies:
olaparib: first FDA approval 2014 (LYNPARZA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 605 Ovarian Neoplasms studies recruiting now, 442 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.
This study: 18 Years to 130 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, olaparib is the treatment under test here. Read study by study →
69 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 17 · Phase 2 35 · Phase 3 17 · Phase 4 3
First in 2005; this study’s year is marked. 6 started in 2020.
By drug class, each counting the studies that test any of its medicines:
Median enrollment 97 across the 69 interventional studies. Of the 32 that completed or were terminated, 16 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 69 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
70 studies in Ovarian Neoplasms by AstraZeneca: 8 open now, 20 under way, 6 of them phase 3. Of 45 finished, 15 (33%) have results posted.
Among the 70 studies in Ovarian Neoplasms by AstraZeneca, this one is the 45th largest by enrollment of the 47 interventional ones that give a count, is one of 6 that started in 2020, is one of 12 in phase 2, and was the 45th registered.
AstraZeneca’s Ovarian Neoplasms studies by the year they started, since 2001.
5 of the studies testing olaparib in Ovarian Neoplasms that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04421963Phase 3AstraZenecaRoll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib | 2027-04-06 |
| NCT03579316M.D. Anderson Cancer CenterAdavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | 2026-12-31 |
| NCT07371104Daewoong Pharmaceutical Co. LTD.Bioequivalence Study of DWZ2501 in Patients With Advanced BRCA-mutated High-grade Ovarian Cancer | 2027-03 |
| NCT07460180The Netherlands Cancer InstituteThe PROOV Study: Exploiting the Synergistic Effect of PARP Inhibition With Cisplatin and Hyperthermia During Interval Cytoreductive Surgery and HIPEC in Ovarian Cancer | 2027-05-01 |
| NCT03943173M.D. Anderson Cancer CenterOlaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before Surgery | 2027-06-27 |
Add all 5 to your calendar (.ics) → With an account.
Among the 69 studies testing olaparib in Ovarian Neoplasms, from their registry updates:
Among AstraZeneca’s 70 in Ovarian Neoplasms:
This tab as a report to print or save as PDF → With an account.
To investigate the effectiveness and tolerability of a second maintenance treatment in participants with platinum-sensitivity relapsed (PSR) epithelial ovarian cancer, who have previously received PARPi maintenance treatment and who have benefit (complete response [CR] or partial response [PR]) or stable disease (SD) from further platinum based chemotherapy.
This is a Phase II, randomised, multicentre study to investigate the efficacy and tolerability of a second maintenance treatment in participants with PSR epithelial ovarian cancer, who have previously received PARPi maintenance treatment and who have benefit (CR or PR) or SD from further platinum based chemotherapy.
Participants will be recruited globally from approximately 120 study sites in the USA, Canada, Middle East and Europe.
Approximately 192 participants fulfilling all of the inclusion criteria and none of the exclusion criteria will be randomised in a 1:1:1 ratio to the following 3 treatment arms (64 participants per arm):
The olaparib and placebo arms will be double blinded, whereas the ceralasertib+olaparib arm will be open label. It is expected that approximately 320 participants will be screened.
The study achieved First Subject In date, but enrollment equals 0 as 7 participants have signed the Informed Consent Form (ICF) and were later screen failed.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Provide informed consent for the genetic sampling and analyses. If a participant declines to participate in the genetics research, there will be no penalty or loss of benefit to the participant. A participant who declines genetics research participation will not be excluded from any other aspect of the main study.
Exclusion Criteria:
Participants with symptomatic uncontrolled .
History of another primary except for:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received ceralasertib 160 mg QD PO on Days 1 to 7 plus olaparib 300 mg BD PO continuous (28 day cycle).
Drug: Olaparib · Drug: Ceralasertib
Olaparib 300 mg BD PO daily continuous.
Drug: Olaparib
Placebo to match olaparib BD PO daily continuous.
Drug: Placebo to match olaparib
Olaparib 300 mg BD (2 × 150 mg tablets) continually in the olaparib monotherapy and ceralasertib+olaparib treatment arms.
Also known as: AZD2281
Ceralasertib 160 mg QD (2 × 80 mg tablets) from Days 1 to 7 (inclusive) of every 28-day cycle.
Also known as: AZD6738
Per olaparib
Progression free survival (PFS)
To assess the efficacy of maintenance olaparib monotherapy and ceralasertib+olaparib combination therapy compared with placebo.
Time frame: To assess from the time of randomization until the date of objective disease progression or death (by any cause in the absence of progression) or approximately up to 2.5 years.
Overall survival (OS)
To further assess the efficacy of maintenance olaparib monotherapy and ceralasertib+olaparib combination therapy compared with placebo; and to assess the efficacy of maintenance ceralasertib+olaparib combination therapy compared with olaparib monotherapy.
Time frame: To assess every 8 weeks (±7 days) for first 72 weeks following objective disease progression or treatment discontinuation and then every 12 weeks, up to approximately 2.5 years.
Time to second progression
To further assess the efficacy of maintenance olaparib monotherapy and ceralasertib+olaparib combination therapy compared with placebo; and to assess the efficacy of maintenance ceralasertib+olaparib combination therapy compared with olaparib monotherapy. A participant's second progression status is defined according to the local standard clinical practice and may involve any of; investigator assessment of radiological progression, cancer antigen 125 (CA 125) progression, symptomatic progression or death.
Time frame: To assess every 8 weeks (±7 days) for first 72 weeks following objective disease progression or treatment discontinuation and then every 12 weeks, up to approximately 2.5 years.
Objective response rate
To further assess the efficacy of maintenance olaparib monotherapy and ceralasertib+olaparib combination therapy compared with placebo; and to assess the efficacy of maintenance ceralasertib+olaparib combination therapy compared with olaparib monotherapy.
Time frame: At baseline, every 8 weeks for first 72 weeks, then every 12 weeks after randomization until objective disease progression or approximately up to 2.5 years.
Duration of response
To further assess the efficacy of maintenance olaparib monotherapy and ceralasertib+olaparib combination therapy compared with placebo; and to assess the efficacy of maintenance ceralasertib+olaparib combination therapy compared with olaparib monotherapy.
Time frame: At baseline, every 8 weeks for first 72 weeks, then every 12 weeks after randomization until objective disease progression or approximately up to 2.5 years.
Percentage change in tumour size
To further assess the efficacy of maintenance olaparib monotherapy and ceralasertib+olaparib combination therapy compared with placebo.
Time frame: At baseline, every 8 weeks for first 72 weeks, then every 12 weeks after randomization until objective disease progression or approximately up to 2.5 years.
Plasma concentration data for olaparib and ceralasertib
To evaluate the pharmacokinetic (PK) exposure of ceralasertib+olaparib combination therapy.
Time frame: At cycle 1 Day 1 and Day 7
Change from baseline in European Organisation for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC-QLQ) C30
To assess the impact of maintenance olaparib monotherapy and ceralasertib+olaparib combination therapy compared with placebo on participants' symptoms, functioning, and Health-related quality of life (HRQoL). Questions are grouped into functional scales, symptom scales, a global health status / quality of life (QoL) scale, assessing additional symptoms commonly reported by cancer participants, and the financial impact of the disease. All but 2 questions are rated on a 4 point verbal rating scale: "Not at all," "A little," "Quite a bit," and "Very much." The 2 questions concerning global health status and QoL have 7 point scales with ratings ranging from "Very poor" to "Excellent." For each of the 15 domains, final scores are transformed such that they range from 0 to 100, where higher scores indicate better functioning, better QoL, or worse symptoms.
Time frame: At Cycle1 Day 1, every 4 weeks from Cycle 1 Day 1 until treatment discontinuation, and follow-up 30 days after last dose of study medication.
Change from baseline in EORTC-QLQ-OV28
To assess the impact of maintenance olaparib monotherapy and ceralasertib+olaparib combination therapy compared with placebo on participants' symptoms, functioning, and HRQoL It consists of 28 items assessing abdominal/gastrointestinal symptoms (6 items), peripheral neuropathy (2 items), other chemotherapy side effects (5 items), hormonal symptoms (2 items), body image (2 items), attitudes to disease/treatment (3 items), sexuality (4 items) and 4 other single items. All questions are rated on a 4 point verbal rating scale: "Not at all," "A little," "Quite a bit," and "Very much." Final scores are transformed such that they range from 0 to 100, where higher scores indicate greater functioning, greater QoL, or greater level of symptoms.
Time frame: At Cycle1 Day 1, every 4 weeks from Cycle 1 Day 1 until treatment discontinuation, and follow-up 30 days after last dose of study medication.
Time to earliest progression by RECIST 1.1 or CA-125 or death
Time to progression by RECIST 1.1 or CA-125 progression or death is defined as the time from randomisation to the earlier date of RECIST 1.1 or CA-125 progression or death by any cause.
Time frame: At baseline, every 8 weeks for first 72 weeks, then every 12 weeks after randomization until objective disease progression or approximately up to 2.5 years.
Number of participants with adverse events (AEs)
To assess the safety and tolerability of maintenance olaparib monotherapy and ceralasertib+olaparib combination therapy compared with placebo.
Time frame: From Cycle 1 Day 1 to follow-up 30 days after the last dose of study medication.
Number of participants with abnormal physical examination
To assess the safety and tolerability of maintenance olaparib monotherapy and ceralasertib+olaparib combination therapy compared with placebo.
Time frame: From Cycle 1 Day 1 to follow-up 30 days after the last dose of study medication.
Number of participants with abnormal Eastern Cooperative Oncology Group (ECOG) performance status (PS)
To assess the safety and tolerability of maintenance olaparib monotherapy and ceralasertib+olaparib combination therapy compared with placebo.
Time frame: From Cycle 1 Day 1 to follow-up 30 days after the last dose of study medication.
Number participants with abnormal systolic and diastolic blood pressure
To assess the safety and tolerability of maintenance olaparib monotherapy and ceralasertib+olaparib combination therapy compared with placebo.
Time frame: From Cycle 1 Day 1 to follow-up 30 days after the last dose of study medication.
Number of participants with abnormal pulse
To assess the safety and tolerability of maintenance olaparib monotherapy and ceralasertib+olaparib combination therapy compared with placebo.
Time frame: From Cycle 1 Day 1 to follow-up 30 days after the last dose of study medication.
Number of participants with abnormal body temperature
To assess the safety and tolerability of maintenance olaparib monotherapy and ceralasertib+olaparib combination therapy compared with placebo.
Time frame: From Cycle 1 Day 1 to follow-up 30 days after the last dose of study medication.
Number of participants with abnormal electrocardiogram
To assess the safety and tolerability of maintenance olaparib monotherapy and ceralasertib+olaparib combination therapy compared with placebo.
Time frame: From Cycle 1 Day 1 to follow-up 30 days after the last dose of study medication.
Number of participants with abnormal hemoglobin (Hb)
To assess the safety and tolerability of maintenance olaparib monotherapy and ceralasertib+olaparib combination therapy compared with placebo.
Time frame: From Cycle 1 Day 1 to follow-up 30 days after the last dose of study medication.
Number of participants with abnormal leukocyte count
To assess the safety and tolerability of maintenance olaparib monotherapy and ceralasertib+olaparib combination therapy compared with placebo.
Time frame: From Cycle 1 Day 1 to follow-up 30 days after the last dose of study medication.
Number of participants with abnormal absolute neutrophil count (ANC)
To assess the safety and tolerability of maintenance olaparib monotherapy and ceralasertib+olaparib combination therapy compared with placebo.
Time frame: From Cycle 1 Day 1 to follow-up 30 days after the last dose of study medication.
Number of participants with abnormal absolute lymphocyte count
To assess the safety and tolerability of maintenance olaparib monotherapy and ceralasertib+olaparib combination therapy compared with placebo.
Time frame: From Cycle 1 Day 1 to follow-up 30 days after the last dose of study medication.
Number of participants with abnormal platelet count
To assess the safety and tolerability of maintenance olaparib monotherapy and ceralasertib+olaparib combination therapy compared with placebo.
Time frame: From Cycle 1 Day 1 to follow-up 30 days after the last dose of study medication.
Number of participants with abnormal mean cell volume
To assess the safety and tolerability of maintenance olaparib monotherapy and ceralasertib+olaparib combination therapy compared with placebo.
Time frame: From Cycle 1 Day 1 to follow-up 30 days after the last dose of study medication.
Number of participants with abnormal serum creatinine
To assess the safety and tolerability of maintenance olaparib monotherapy and ceralasertib+olaparib combination therapy compared with placebo.
Time frame: From Cycle 1 Day 1 to follow-up 30 days after the last dose of study medication.
Number of participants with abnormal serum total bilirubin
To assess the safety and tolerability of maintenance olaparib monotherapy and ceralasertib+olaparib combination therapy compared with placebo.
Time frame: From Cycle 1 Day 1 to follow-up 30 days after the last dose of study medication.
Number of participants with abnormal serum alanine aminotransferase (ALT), aspartate aminotransferase (AST) and alkaline phosphatase
To assess the safety and tolerability of maintenance olaparib monotherapy and ceralasertib+olaparib combination therapy compared with placebo.
Time frame: From Cycle 1 Day 1 to follow-up 30 days after the last dose of study medication.
Number of participants with abnormal serum potassium, calcium and sodium
To assess the safety and tolerability of maintenance olaparib monotherapy and ceralasertib+olaparib combination therapy compared with placebo.
Time frame: From Cycle 1 Day 1 to follow-up 30 days after the last dose of study medication.
Number of participants with abnormal plasma glucose
To assess the safety and tolerability of maintenance olaparib monotherapy and ceralasertib+olaparib combination therapy compared with placebo.
Time frame: From Cycle 1 Day 1 to follow-up 30 days after the last dose of study medication.
Number of participants with abnormal serum lactate dehydrogenase
To assess the safety and tolerability of maintenance olaparib monotherapy and ceralasertib+olaparib combination therapy compared with placebo.
Time frame: From Cycle 1 Day 1 to follow-up 30 days after the last dose of study medication.
Number of participants with abnormal creatinine clearance
To assess the safety and tolerability of maintenance olaparib monotherapy and ceralasertib+olaparib combination therapy compared with placebo.
Time frame: From Cycle 1 Day 1 to follow-up 30 days after the last dose of study medication.
Number of participants with abnormal serum urea or blood urea nitrogen
To assess the safety and tolerability of maintenance olaparib monotherapy and ceralasertib+olaparib combination therapy compared with placebo.
Time frame: From Cycle 1 Day 1 to follow-up 30 days after the last dose of study medication.
Number of participants with abnormal plasma total protein
To assess the safety and tolerability of maintenance olaparib monotherapy and ceralasertib+olaparib combination therapy compared with placebo.
Time frame: From Cycle 1 Day 1 to follow-up 30 days after the last dose of study medication.
Number of participants with abnormal urine Hb/erythrocytes/blood
To assess the safety and tolerability of maintenance olaparib monotherapy and ceralasertib+olaparib combination therapy compared with placebo.
Time frame: From Cycle 1 Day 1 to follow-up 30 days after the last dose of study medication.
Number of participants with abnormal urine protein/albumin
To assess the safety and tolerability of maintenance olaparib monotherapy and ceralasertib+olaparib combination therapy compared with placebo.
Time frame: From Cycle 1 Day 1 to follow-up 30 days after the last dose of study medication.
Number of participants with abnormal urine glucose
To assess the safety and tolerability of maintenance olaparib monotherapy and ceralasertib+olaparib combination therapy compared with placebo.
Time frame: From Cycle 1 Day 1 to follow-up 30 days after the last dose of study medication.
Number of participants with abnormal urine ketones
To assess the safety and tolerability of maintenance olaparib monotherapy and ceralasertib+olaparib combination therapy compared with placebo.
Time frame: From Cycle 1 Day 1 to follow-up 30 days after the last dose of study medication.
Number of participants with abnormal urine pH
To assess the safety and tolerability of maintenance olaparib monotherapy and ceralasertib+olaparib combination therapy compared with placebo.
Time frame: From Cycle 1 Day 1 to follow-up 30 days after the last dose of study medication.
Number of participants with abnormal specific gravity
To assess the safety and tolerability of maintenance olaparib monotherapy and ceralasertib+olaparib combination therapy compared with placebo.
Time frame: From Cycle 1 Day 1 to follow-up 30 days after the last dose of study medication.
Number of participants with abnormal urine bilirubin
To assess the safety and tolerability of maintenance olaparib monotherapy and ceralasertib+olaparib combination therapy compared with placebo.
Time frame: From Cycle 1 Day 1 to follow-up 30 days after the last dose of study medication.
European quality of life 5 dimensions, 5 level
To assess both European quality of life descriptive system and European quality of life visual analogue scale (EQ VAS). The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The participant is asked to indicate his health state by ticking the box next to the most appropriate statement in each of the five dimensions. This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the participant's health state. The EQ VAS records the participant's self-rated health on a vertical visual analogue scale, where the endpoints are labelled 'the best health you can imagine' and 'the worst health you can imagine'.
Time frame: From Cycle 1 Day 1 to follow-up 30 days after the last dose of study medication.
Patient Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
To assess tolerability from the participants perspective. PRO-CTCAE is an item library of symptomatic AEs experienced by patients while undergoing treatment of their cancer. PRO questionnaires completed at site visits must be completed prior to treatment administration
Time frame: From Cycle 1 Day 1 to follow-up 30 days after the last dose of study medication.
Patient global impression of severity
To assess overall severity of participant's cancer symptoms over the past week. The item is rated using a 6 point verbal rating scale from "No Symptoms" to "Very Severe".
Time frame: From Cycle 1 Day 1 to follow-up 30 days after the last dose of study medication.
Patient global impression of change
To assess overall change in health condition since the start of study treatment(s). The item is rated using a 7 point Likert type scale from "Much Better" to "Much Worse".
Time frame: From Cycle 1 Day 1 to follow-up 30 days after the last dose of study medication.
Patient global impression-treatment tolerability
To asses overall bother associated with symptomatic AEs. The item is rated using a 6 point verbal scale from "Not at All" to "Very Much".
Time frame: From Cycle 1 Day 1 to follow-up 30 days after the last dose of study medication.
Patient global impression-benefit risk
To asses the participant's perception of the overall benefits and risks of treatment. The 5 items to be assessed included overall trial experience, efficacy, side effects, convenience, and overall assessment of the benefits and harms of treatment. Items are rated on 5 or 6 point verbal rating or Likert type scales.
Time frame: From Cycle 1 Day 1 to 12 weeks and 16 weeks of study medication.
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please re-refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com
Ran from Aug 2020 to primary completion in Jan 2021, 5 months.
How these figures are worked out, and which studies are left out of them.
This study is withdrawn, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Olaparib · Ceralasertib